Clinical Analysis of Apatinib in the Treatment of Patients with Residual Tumor after Radical Chemoradiotherapy for Locally Advanced Cervical Cancer

: There is no standard treatment for locally advanced cervical cancer, patients with residual tumor after radical concurrent chemoradiotherapy. This study was to investigate the short-term efficacy and safety of the targeted drug apatinib mesylate in patients with tumor residual after radical chemoradiotherapy for locally advanced cervical cancer. Eight patients with residual tumors after localized concurrent chemoradiotherapy with locally advanced cervical cancer were treated with apatinib (250 mg once daily, orally). The short-term efficacy and safety of the eight patients treated with apatinib were initially evaluated. Total Effectiveness (ORR) 37.5% and disease control rate (DCR) 100.0%. The toxicity and side effects were light, mainly manifested as 37.5% of hand-foot syndrome, 37.5% of proteinuria, 25.0% of hypertension, 12.5% of fatigue, 12.5% of rash, and 12.5% of vomiting. No serious toxic side effects associated with the drug were observed. Apatinib mesylate can be safely used in patients with residual tumor after radical chemoradiotherapy for locally advanced cervical cancer. The short-term effect is positive and the side effects are low.